Podcast: Thermo Fisher’s Meron Mathias On Why Environmental Sustainability Must Be A Top Priority

Company Drives For Sustainability Compliance 'In The Right Way'

Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.

Citeline-Thermo Fisher Scientific

Thermo Fisher Scientific was one of the first companies in its peer group to have its near and long-term net-zero targets validated by the Science Based Targets initiative (SBTi). The company aims to achieve net zero by 2050, and has set a series of interim milestones, including a recently added global energy target based on renewable electricity.

In this podcast, Meron Mathias explains Thermo Fisher’s sustainability targets within the E in ESG. She conveys the importance of concurrent diversity, equity and inclusivity (DEI) compliance, to help ensure all elements of the sustainability agenda progress at the required pace. She takes forward the position she laid out in a 2023 interview with In Vivo. (Also see "The E in ESG: Thermo Fisher On Why The ‘How’ Is More Important Than The ‘When’" - In Vivo, 22 May, 2023.)

Since joining the company as head of CSR and sustainability in 2020, and then being elevated two years later to vice president, Meron has focused on enabling Thermo Fisher’s customers to make the world healthier, cleaner and safer through a combination of innovative technologies and ethical business processes.

She explains the important elements in compliance, what guides Thermo Fisher’s policy on compliant innovation and R&D, and the “five environmental impact areas” it factors into the innovation process to help ensure: reduced presence of hazardous chemicals, reduced waste generation, enhanced energy efficiency, use of responsible packaging practices and promotion of product longevity.

Citeline · Sustainable By Design: Thermo Fisher's Meron Mathias On ESG Compliance And The Competitive Edge

Meron highlights that innovating “in the right ways to support environmental sustainability” provides a competitive advantage. She stresses: “Our Greener by design program has shown that that greener approaches can often lower costs for both the company and our customers.”

But because business aims and sustainability must go hand in hand, Thermo Fisher has established a framework to help ensure its supply chain mirrors its own sustainability efforts and achievements.

And operationally, Thermo Fisher employees play a key role in the company’s community engagement. Its practical process improvement (PPI) program empowers all colleagues to drive efficiency, and an internal generative AI platform enables staff to leverage the benefits of AI to improve productivity.

Meron says: “We take an approach that's really looking at operations, partnerships and innovation to drive progress. There will continue to be opportunities to adapt our approach as new innovations come onto the market. We all have to remain agile and look for those levers to accelerate our progress.”

Podcast Themes And Timestamps:

1.38 Sustainability compliance “in the right way” – Thermo Fisher’s priorities

3.57 Thermo Fisher’s sustainability timelines and targets

5.53 ESG guiding strategies and “going the extra mile”

10.43 How business planning is influenced by the environmental agenda at Thermo Fisher

13.02 ESG compliance cuts across all the whole company. More complex regulations are coming into force

14.25 Innovating “in the right way” – the adoption of green approaches while reconciling business needs with a responsible market stance

15.30 Bringing the whole value chain on board at the same time: the primacy of partnerships, investing in training and the role of innovation

18.29 Supply chain partners who have set, or committed to, science-based targets; progress towards Thermo Fisher’s sign-up target of 90% of suppliers by spend

19.54 Diversity – the S in ESG – and the need to make concurrent progress alongside the environmental agenda

21.36 Innovation and R&D – new approaches to deliver competitive edge

22.59  “Find a better way every day”: Thermo Fisher’s “five impact areas” on the innovation journey

25.06  Colleagues’ roles in ESG, including the PPI concept at Thermo Fisher

26.37  Thermo Fisher has come far in ESG: how far has it yet to go?

27.49 Final ESG comments, completing a resource that others can refer to

29.47Thank you, Meron

More from ESG

Infographic: Analyzing The Gap In Women’s Health Care

 

Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.

Growing Calls For Labelling Changes With Obesity Patients In Mind

 
• By 

Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.

Global Regulator Action To Improve Diversity In Clinical Trials

 
• By 

As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment. 

Providing The Balance Between Medtech Innovation And Providers’ Sustainability

 
• By 

Royal Philips is at the forefront of the driving environmental sustainability along the Scope 1-2-3 chain. The company hosted a round table in Amsterdam to hear experiences from providers.

More from In Vivo

TechBio’s Next Wave: Where AI Meets Biology And Investment Opportunity

 
• By 

TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.

Deals In Depth: February 2025

 
• By 

Three $1bn+ alliances were penned in February, and one exceeded $2bn.

Mirum’s Rare Disease Strategy: A Blueprint For Sustainable Growth

 
• By 

From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.